David M. Albala, MD; E. David Crawford, MD; and Phillip J. Koo, MD, presented “PSMA PET for Improving the Diagnosis, Treatment, and Management of Prostate Cancer – AUA Abstract Review” for the Grand Rounds in Urology audience in December 2022.

How to cite: Albala, David M.; Crawford, E. David; Koo, Phillip J. “PSMA PET for Improving the Diagnosis, Treatment, and Management of Prostate Cancer – AUA Abstract Review.” December 2022. Accessed Jun 2024. https://grandroundsinurology.com/psma-pet-for-improving-the-diagnosis-treatment-and-management-of-prostate-cancer-aua-abstract-review/

PSMA PET for Improving the Diagnosis, Treatment, and Management of Prostate Cancer – AUA Abstract Review

In this discussion, supported by Lantheus, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego, joins Philip J. Koo, MD, Division Chief of Diagnostic Imaging and Northwest Region Oncology Physician Executive at the Banner MD Anderson Cancer Center in Phoenix, Arizona, and David M. Albala, MD, Chief of Urology at Crouse Hospital in Syracuse, New York, to discuss seven abstracts from AUA 2022 highlighting PMSA PET imaging and the future of prostate cancer management. From PSMA-targeted fluorophore for improved cancer visualization to PSMA testing prior to salvage radiation therapy, the presenters cover a range of topics demonstrating the utility of PSMA PET imaging.

Works cited (in order of reference):

Meijer D, Eppinga W, Mohede R, et.al. Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/ Computed Tomography is Associated with Improved Oncological Outcome in Men who Underwent Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer [AUA abstract PD22-02]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e402.

Kuppermann D, Calais J, Brisbane W, et.al. Prostate biopsy targeted to Prostate Specific Membrane Antigen (PSMA) foci [AUA abstract MP09-20]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e144.

Bahler C, Green M, Tann M, et.al. Predicting Extra-prostatic Extension (EPE) for surgical guidance in prostate cancer: A comparison of biopsy pathology, multiparametric MRI, and PSMA-PET [AUA abstract PD27-01]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e493.

Nickols N, Berenji G, Kane N. Quantitative Piflufolastat F18 (PSMA) Scan Indices as a Response Imaging-Biomarker to Androgen Deprivation Therapy in Veterans with Newly Diagnosed Metastatic Prostate Cancer [AUA abstract PD35-04]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e628.

Fleming, Mark. Impact of 18F-rhPSMA-7.3 PET on upstaging of patients with prostate cancer recurrence: Results from the prospective, phase 3, multicenter, SPOTLIGHT study [AUA abstract PLLBA-02]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e1047.

Nguyen H, Antaris A, Van den Berg N. Results of the Phase 1 safety and efficacy Prostate Specific Membrane Antigen (PSMA) targeting fluorophore for image guided surgery in patients undergoing robotic prostatectomy [AUA abstract PD54-11]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e920.

Scuderi S, Mazzone E, Gandaglia G. The Impact Of Histological Variants On The Performance Characteristics Of 68Ga-PSMA PET/CT In The Primary And Recurrent Setting [AUA abstract PD60-03]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e1025.


Supported by


About the Authors

David M. Albala, MD
Associated Medical Professionals
Syracuse, New York


E. David Crawford, MD
University of California San Diego
La Jolla, California


Phillip J. Koo, MD
Banner MD Anderson Cancer Center
Phoenix, Arizona